or with DNA microsatellite instability,7 8 abnormalities that are well recognised in colorectal adenomas and carcinomas. Otori et al (see page 660) describe a molecular pathological study of metaplastic polyps in which they find K-ras mutations in nine (47%) of 19, but no evidence of APC or p53 lesions. Another recent study presented similar findings with K-ras mutations in 22% (five of 22) of polyps.9 Collectively, these observations represent a significant challenge to the view that metaplastic polyps are non-neoplastic lesions and although they do not prove conclusively a clonal origin, they strengthen the proposal that these polyps are benign neoplasms rather than hyperplastic lesions of contiguous crypts. Their lack of APC mutations correlates with the absence of dysplasia,9 while the chance occurrence ofAPC mutation within metaplastic polyps is likely to explain the rare development of adenomas within them (so called mixed metaplasticadenomatous polyps).'
If metaplastic polyps are true neoplasms resulting from somatic mutation followed by clonal expansion, their epidemiological' and anatomical2 association with sporadic colorectal adenomas and carcinomas can be explained by the fact that factors governing mutation frequency would be expected to influence the incidence of both types of tumour. Accumulation of somatic mutations with age would also explain the increasing prevalence of metaplastic polyps in older people. The fundamental difference between metaplastic polyps and adenomas would be that whereas both are neoplasms, it is only adenomas that possess the inherent capacity for malignant progression. Conceivably, the genetic lesion that induces metaplastic polyps merely leads to a re-setting of the normal intracryptal balance between proliferation, differentiation and cell loss to a new steady state level. Although this would be sufficient to result in the typical phenotypic features of the metaplastic polyp, it would not predispose to malignant progression unless the lesion acquired, by chance, some additional mutation, such as in the APC gene, to disrupt this stability. The fact that metaplastic polyps virtually never grow to more than a few millimetres in size would be consistent with this newly acquired steady state.
What, if anything, does the occurrence of K-ras mutations in 22-47% of metaplastic polyps tell us about their origin? The proportion of affected lesions seems rather low to suggest that this mutation is the fundamental genetic event involved, although the figure of 47% is similar to the observed frequency of K-ras mutation in adenomas. The colonic lesions that are consistently accompanied by K-ras mutation are so called aberrant crypt foci (ACF),9 tiny hyperplastic oligocryptal lesions that can only be visualised with a dissecting microscope or a magnifying colonoscope. Not surprisingly, they are commoner in colons bearing carcinomas. A small minority of these ACFs also harbour APC mutations,9 in which case they show histological features of dysplasia and are thought to progress to adenomas. The great majority ofACFs seem to be non-progressive and may eventually regress through apoptosis.1°However, some show small epithelial infoldings into the crypt that give rise to a serrated appearance mimicking mini-metaplastic polyps." l A plausible scenario, therefore, is that these lesions have acquired a metaplastic polyp inducing mutation and are destined to evolve into macroscopic metaplastic polyps. This is not to imply that all metaplastic polyps arise from ACFs -the essential mutation could arise in normal epithelium giving rise to metaplastic polyps de novo (which would not have K-ras mutations) -but it seems that the metaplastic polyp mutation and mutant K-ras might act synergistically in the development of the established lesion.
What are the implications of metaplastic polyps being true neoplasms for the practising clinician and for strategies for colorectal cancer prevention? Should it alter our approach to the management of patients with such lesions? The answer is a definite 'no'. Even if metaplastic polyps are tumours, there is firm pathological and clinical evidence that they are not lesions with any significant risk of malignant transformation and they can be safely left alone. The only exception is the rare, larger (> 1 cm), often pedunculated lesion that may turn out to be a mixed metaplastic-adenomatous polyp on histological examination. What about multiple metaplastic polyps? It 
